(Q38518602)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

title

Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

15

Jennifer J Griggs

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Megan E V Caram

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Cui Guo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Monika Leja

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Jeffrey Smerage

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

N Lynn Henry

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Donald Giacherio

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Melvyn Rubenfire

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Anne Schott

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Melinda Davis

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Daniel F Hayes

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Catherine Van Poznak

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Daniel L Hertz

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Mousumi Banerjee

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

language of work or name

English

0 references

publication date

7 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

16 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

152

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

163-172

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050157%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10549-015-3454-8

16 February 2020

exact match

0 references

cites work

Early detection and prediction of cardiotoxicity in chemotherapy-treated patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

The Natural History of Congestive Heart Failure: The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Representation of older patients in cancer treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Cardiac troponin-I and risk of heart failure: a community-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Plasma brain natriuretic peptide concentration: impact of age and gender

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Clinical cardiac tolerability of trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Protective effects of carvedilol against anthracycline-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Decline in the use of anthracyclines for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8

Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardio

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3454-8